Review
Pharmacology & Pharmacy
Maria John Newton Amaldoss, Jia-Lin Yang, Pramod Koshy, Ashwin Unnikrishnan, Charles C. Sorrell
Summary: Inorganic nanoparticles used for drug delivery in cancer treatment offer numerous advantages, such as maximizing therapeutic effect through targeting ligands and minimizing side-effects. They have shown promising combined therapeutic capabilities, including anticancer effects and inhibition of cancer cell signaling pathways. Inorganic nanoparticles serve as synergistic platforms for RNA interference and as drug delivery agents for targeting cancer cell signaling pathways.
DRUG DISCOVERY TODAY
(2022)
Article
Pharmacology & Pharmacy
Xiaomin Wang, Jun Xu, Yiming Sun, Siyuwei Cao, Hanlin Zeng, Nan Jin, Matthew Shou, Shuai Tang, Yi Chen, Min Huang
Summary: This study discovers that the hedgehog (Hh) pathway regulates the histone methylation landscape in breast cancer, promoting histone acetylation and enhancing the therapeutic effect of histone deacetylase (HDAC) inhibitors, providing new treatment options for triple-negative breast cancer (TNBC).
ACTA PHARMACEUTICA SINICA B
(2023)
Review
Oncology
Melanie Kirkby, Alyanna M. Popatia, Jessie R. Lavoie, Lisheng Wang
Summary: The presence of estrogen receptor beta, the androgen receptor, and the glucocorticoid receptor on triple-negative breast cancer cells has presented new opportunities for treatment. This review explores the role of these receptors in the progression of triple-negative breast cancer and provides an overview of clinical trials targeting these receptors.
Review
Biochemistry & Molecular Biology
Yiling Wang, Audrey Minden
Summary: Breast cancer is the second leading cause of death for women worldwide. Combination therapies have emerged as promising treatment options, offering increased effectiveness and lower toxicity compared to monotherapies. The use of multidisciplinary technologies has the potential to further optimize combination therapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Pharmacology & Pharmacy
Tyrillshall S. T. Damiana, Simone U. Dalm
Summary: Radionuclide therapy and targeted radionuclide therapy have gained interest in cancer treatment, but only a small percentage of patients achieve complete response. Therefore, combining these treatments with other anti-cancer therapies may be a promising strategy to improve outcomes.
Article
Neurosciences
Jiyoen Kim, Maria de Haro, Ismael Al-Ramahi, Lorena Laura Garaicoechea, Hyun-Hwan Jeong, Jun Young Sonn, Bakhos Tadros, Zhandong Liu, Juan Botas, Huda Yahya Zoghbi
Summary: Tauopathies are neurodegenerative diseases characterized by the accumulation of tau proteins. A genetic screening of potentially druggable genes identified three genes (USP7, RNF130, and RNF149) that regulate tau levels by targeting the C terminus of CHIP. Knockdown of these genes reduced tau levels and rescued disease phenotypes, suggesting a potential therapeutic strategy for Alzheimer disease and other tauopathies.
Review
Biochemistry & Molecular Biology
James D. D. Fackenthal
Summary: Cancer is a leading cause of death worldwide. Alternative mRNA splicing has recently been recognized as a major contributor to cancer initiation and progression. Cancer cells exhibit different distribution of splicing variants compared to non-cancer cells, and they are more sensitive to drugs targeting the splicing regulatory network. Certain recurring splicing variants have been shown to contribute to tumor progression, while some disruption events result from mutations in splicing regulatory sequences or shifts in balance among naturally occurring splicing variants of mRNAs involved in cell cycle progression and apoptosis regulation. This review explores cancer-related alternative splicing events and potential therapies.
Review
Biochemistry & Molecular Biology
Pedram Moeini, Paulina Niedzwiedzka-Rystwej
Summary: Macrophages, crucial cells of the innate immune system, play a significant role in cancer progression and therapy failure by transforming into tumor-associated macrophages (TAMs) within the tumor microenvironment. This review aims to explore the advantages and disadvantages of TAMs in the immune system.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biotechnology & Applied Microbiology
Shuting Zuo, Jing Wang, Xianquan An, Yan Zhang
Summary: Protein therapeutics is a promising strategy for cancer treatment, but its limited physiological stability and membrane permeability have hindered its clinical application. Researchers have developed Janus MSNNPs to enhance the delivery and therapeutic effect of protein drugs. In vitro and in vivo experiments have shown the high efficacy and low side effects of this approach in breast cancer treatment.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2022)
Editorial Material
Cell Biology
Anna C. Obenauf
Summary: Functional interrogation of cancer and immune cells during tumor evolution uncovers cancer drivers and guides mechanism-based combination therapies.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Review
Immunology
Si-Yuan Zhu, Ke-Da Yu
Summary: Breast cancer is the most commonly diagnosed cancer worldwide, with relapse and metastasis posing significant challenges. Innovative therapeutic strategies, such as cancer vaccines, are needed to address these challenges. Although current results have been disappointing, recent studies suggest the potential of combining vaccines with other treatments for breast cancer.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
Zhijun Zhou, Barish H. Edil, Min Li
Summary: Gastrointestinal cancers, especially pancreatic cancer, pose a significant challenge to public health. Neoadjuvant chemotherapy offers some patients the chance for radical resection. An optimal chemotherapy regimen should maximize anti-tumor efficacy while maintaining manageable safety. Surgical advancements further enhance outcomes for these patients.
Review
Endocrinology & Metabolism
Aleck Hercbergs, Hung-Yun Lin, Shaker A. Mousa, Paul J. Davis
Summary: Thyroid hormone acts on cancer cells through its receptor on the cell surface to promote cell proliferation. It can promote the growth of estrogen receptor-positive breast cancer cells in the absence of estrogen. Additionally, it may contribute to aggressive breast cancer behavior by stimulating immune checkpoint inhibitor gene expression and anti-apoptosis mechanisms.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Review
Oncology
Laura Bracci, Alessia Fabbri, Manuela Del Corno, Lucia Conti
Summary: Colorectal cancer is a major global cause of death, and the current medical treatments are not sufficient to control metastatic disease. Combination therapy involving cytotoxic treatments and non-toxic natural compounds is seen as a promising more effective and safer alternative. Polyphenols found in fruit and vegetables have shown potential for enhancing colorectal cancer therapy, but further clinical studies are needed to definitively prove their value.
Review
Biochemistry & Molecular Biology
Khetam Sounbuli, Nadezhda Mironova, Ludmila Alekseeva
Summary: Neutrophils, the most abundant leukocytes in human blood, have been recognized as important players in the innate immune system and the first line of defense against invading pathogens. Recent studies have revealed their active involvement in the immune response during cancer development. They exhibit both pro-oncogenic and anti-tumor activities under the influence of various mediators in the tumor microenvironment. Furthermore, the existence of different subpopulations of neutrophils challenges the traditional concept of their homogeneity and opens new possibilities for cancer therapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Meeting Abstract
Oncology
Frederique Penault-Llorca, Florence Dalenc, Sylvie Chabaud, Paul Cottu, Djelila Allouache, David Cameron, Jean-Philippe Jacquin, Julien Grenier, Laurence Venat Bouvet, Apurna Jegannathen, Mario Campone, Francesco Del Piano, Marc Debled, Anne-Claire Hardy-Bessard, Sylvie Giacchetti, Philippe Barthelemy, Laure Kaluzinski, Audrey Mailliez, Marie-Ange Mouret-Reynier, Eric Legouffe, Anne Cayre, Mathilde Martinez, Catherine Delbaldo, Delphine Mollon-Grange, E. Jane Macaskill, Matthew Sephton, Laetitia Stefani, Blaha Belgadi, Matthew Winter, Hubert Orfeuvre, Magali Lacroix-Triki, Herve Bonnefoi, Judith Bliss, Jean-Luc Canon, Jerome Lemonnier, Fabrice Andre, Thomas Bachelot
Article
Oncology
Florence Dalenc, Amelie Lusque, Thibault De La Motte Rouge, Barbara Pistilli, Etienne Brain, David Pasquier, Marc Debled, Jean-Christophe Thery, Anthony Goncalves, Isabelle Desmoulins, Christelle Levy, Lionel Uwer, Jean-Marc Ferrero, Jean-Christophe Eymard, Marie-Ange Mouret-Reynier, Anne Patsouris, Jean-Sebastien Frenel, Thierry Petit, Michael Chevrot, Thomas Bachelot, Severine Guiu
Summary: The histological lobular subtype has an impact on the overall survival of patients with metastatic breast cancer. Lobular histology could be considered as a specific entity that requires tailored management. Further studies are needed to determine the management strategies for these patients.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Thomas Bachelot, Paul Cottu, Sylvie Chabaud, Florence Dalenc, Djelila Allouache, Suzette Delaloge, Jean-Philippe Jacquin, Julien Grenier, Laurence Venat Bouvet, Apurna Jegannathen, Mario Campone, Francesco Del Piano, Marc Debled, Anne-Claire Hardy-Bessard, Sylvie Giacchetti, Marie-Ange Mouret-Reynier, Philippe Barthelemy, Laure Kaluzinski, Audrey Mailliez, Eric Legouffe, Matthew Sephton, Judith Bliss, Jean-Luc Canon, Frederique Penault-Llorca, Jerome Lemonnier, David Cameron, Fabrice Andre
Summary: This study investigated the effect of adding everolimus to adjuvant therapy in early breast cancer and found that among high-risk patients, adding everolimus to adjuvant endocrine therapy did not improve disease-free survival. Tolerability was also a concern, with more than half of the patients discontinuing everolimus treatment before the study completion.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Cell Biology
Wanting Shao, Melitta B. Koepke, Theresa Vilsmaier, Alaleh Zati Zehni, Mirjana Kessler, Sophie Sixou, Mariella Schneider, Nina Ditsch, Vincent Cavailles, Udo Jeschke
Summary: The cytoplasmic co-expression of RXR alpha and PPAR gamma in breast cancer patients is associated with shorter survival and tumor aggressiveness markers. This finding is clinically relevant for identifying high-risk breast cancer patients, especially those with early and node-negative disease.
Article
Oncology
Francois-Clement Bidard, Virginia G. Kaklamani, Patrick Neven, Guillermo Streich, Alberto J. Montero, Frederic Forget, Marie-Ange Mouret-Reynier, Joo Hyuk Sohn, Donatienne Taylor, Kathleen K. Harnden, Hung Khong, Judit Kocsis, Florence Dalenc, Patrick M. Dillon, Sunil Babu, Simon Waters, Ines Deleu, Jose A. Garcia Saenz, Emilio Bria, Marina Cazzaniga, Janice Lu, Philippe Aftimos, Javier Cortes, Shubin Liu, Giulia Tonini, Dirk Laurent, Nassir Habboubi, Maureen G. Conlan, Aditya Bardia
Summary: Elacestrant, a novel oral selective estrogen receptor degrader, demonstrated significant improvement in progression-free survival in patients with pretreated estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer, including those with ESR1 mutations, with manageable adverse events.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Serena Di Cosimo, Jose Manuel Perez-Garcia, Meritxell Bellet, Florence Dalenc, Miguel J. Gil Gil, Manuel Ruiz Borrego, Joaquin Gavila, Miguel Sampayo-Cordero, Elena Aguirre, Peter Schmid, Frederik Marme, Joseph Gligorov, Andreas Schneeweiss, Joan Albanell, Pilar Zamora, Duncan Wheatley, Eduardo Martinez-De Duenas, Vicente Caranana, Kepa Amillano, Leonardo Mina, Andrea Malfettone, Javier Cortes, Antonio Llombart-Cussac
Summary: This study provides a comprehensive summary of the safety and tolerability of the combination of endocrine therapy and palbociclib in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. The results confirmed the favorable safety profile of palbociclib regimens with occasional occurrence of venous thromboembolism and interstitial lung disease/pneumonitis, which can be effectively managed without compromising efficacy.
Article
Oncology
Idlir Licaj, Elodie Coquan, Tienhan Sandrine Dabakuyo-Yonli, Sarah Dauchy, Ines Vaz Luis, Cecile Charles, Cedric Lemogne, Olivier Tredan, Laurence Vanlemmens, Christelle Jouannaud, Christelle Levy, Olivier Rigal, Marion Fournier, Thierry Petit, Florence Dalenc, Philippe Rouanet, Jerome Lemonnier, Sibille Everhard, Paul Cottu, Florence Joly
Summary: This study used the CANTO cohort to study the associations between baseline quality of life and chemotherapy dose-reductions (CDRs) or post-chemotherapy toxicities (PCTs). The results showed that baseline physical functioning and fatigue were associated with CDRs and PCTs.
Article
Oncology
Laetitia Collet, Lauriane Eberst, Gauthier Ludovic, Marc Debled, Loana Hrab, Marie-Ange Mouret-Reynier, Isabelle Desmoulins, Anthony Goncalves, Mario Campone, Jean-Marc Ferrero, Etienne Brain, Lionel Uwer, Jean-Christophe Eymard, Veronique Dieras, Gaetane Simon, Marianne Leheurteur, Florence Dalenc, Laurence Vanlemmens, Amelie Darlix, Monica Arnedos, Thomas Bachelot
Summary: A retrospective study on 995 HER2-positive metastatic breast cancer patients found that 13% of patients experienced isolated central nervous system progression after first-line treatment with trastuzumab and pertuzumab. Continuing trastuzumab and pertuzumab therapy after local treatment did not negatively impact survival.
Article
Oncology
Jean-Louis Lacaze, Ciprian Chira, Gauthier Glemarec, Nils Monselet, Thibaut Cassou-Mounat, Eleonora De Maio, Eva Jouve, Carole Massabeau, Clemence Brac de la Perriere, Gabrielle Selmes, Mony Ung, Vincent Nicolai, Bastien Cabarrou, Florence Dalenc
Summary: This study retrospectively collected data from 998 consecutive patients with synchronous or metachronous metastatic breast cancer (MBC) and found that 15.8% of cases met the definition of oligometastatic breast cancer (OMBC). Among OMBC patients, 88% had 1-3 metastases and 86.7% had only one organ involved. Different subtypes of OMBC were associated with different metastatic sites. HR+/HER2- subtype was associated with bone metastases, HER2+ subtype was associated with brain lesions, and HR-/HER2- subtype was associated with lymph node metastases. In conclusion, OMBC is a heterogeneous entity that requires specific management strategies for different subgroups.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Pharmacology & Pharmacy
Florent Puisset, Felicien Le Louedec, Florence Dalenc, Lorene Verguet, Eleonora De Maio, Jean Louis Lacaze, Marion Montastruc, Mony Ung, Camille Vinson, Sophie Perriat, Sandrine Pacher, Etienne Chatelut, Melanie White Koning
Summary: This study assessed the clinical outcome of dose-banding (DB) in patients receiving paclitaxel for cancer treatment. The results showed that DB did not affect the clinical outcome of patients.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Fabian Garrido, Carl Mathis Wild, Udo Jeschke, Christian Dannecker, Doris Mayr, Vincent Cavailles, Sven Mahner, Bernd Kost, Helene H. H. Heidegger, Aurelia Vattai
Summary: In this study, the expression of progesterone receptor A (PRA) in cervical cancer tissue samples was evaluated and correlated with clinicopathological parameters. It was found that PRA expression was positively correlated with FIGO classification scores and significantly overexpressed in adenocarcinomas compared to squamous epithelial carcinoma subtypes. PRA expression was also associated with HPV virus protein E6, p16, and EP3. Survival analyses showed that PRA was a negative prognosticator in patients with cervical adenocarcinoma, and the simultaneous expression of RIP140 and PRA was associated with the worst survival outcome.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Correction
Oncology
Francois Poumeaud, Anna Fontanier, Jeremie Dion, Quentin Mathevet, Olivier Cointault, Emmanuelle Uro-Coste, Celine Marty, Florence Dalenc, Pierre Girardie, Anais Rataboul
FRONTIERS IN ONCOLOGY
(2023)
Article
Public, Environmental & Occupational Health
Florian Martinet-Kosinski, Sebastien Lamy, Eric Bauvin, Florence Dalenc, Charlotte Vaysse, Pascale Grosclaude
Summary: Too few women with invasive breast cancer are informed of the risk of hypofertility after chemotherapy, but this risk can be prevented by offering gamete preservation by a specialized team. We believe that if more women were informed about gamete preservation, more of them would accept it.
FRONTIERS IN PUBLIC HEALTH
(2023)
Meeting Abstract
Oncology
Hope S. Rugo, Aditya Bardia, Frederik Marine, Javier Cortes, Peter Schmid, Delphine Loirat, Olivier Tredan, Eva Ciruelos, Florence Dalenc, Patricia Gomez Pardo, Komal L. Jhaveri, Rosemary Delaney, Olivia Fu, Lanjia Lin, Wendy Verret, Sara M. Tolaney
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Virginia G. Kaklamani, Aditya Bardia, Philippe Georges Aftimos, Javier Cortes, Janice M. Lu, Patrick Neven, Guillermo Streich, Alberto J. Montero, Frederic Forget, Marie-Ange Mouret-Reynier, Joohyuk Sohn, Donatienne Taylor, Kathleen Kiernan Harnden, Hung T. Khong, Judit Kocsis, Florence Dalenc, Patrick Michael Dillon, Giulia Tonini, Kris Grzegorzewski, Francois-Clement Bidard
JOURNAL OF CLINICAL ONCOLOGY
(2022)
